AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants - WTNZ FOX 43 Knoxville, TN

AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Advanced Inhalation Therapies (AIT)

REHOVOT, Israel, January 23, 2014 /PRNewswire/ --

Advanced Inhalation Therapies (AIT), a leader in the development of nitric oxide (NO) therapeutics for the treatment of infectious respiratory diseases, announced today that its lead investigator will present clincial trial results at the upcoming 2014 American Thoracic Society (ATS)  International Conference Committee in San Diego, California, May16 to 21, 2014.

The presentation entitled  "Prospective, double-blind, randomized controlled trial, evaluation of the safety and tolerability of intermittent high-dose inhaled nitric oxide in infants with acute bronchiolitis," will be given by Professor Asher Tal, M.D., the principal investigator of the trial. Professor Tal is a professor of pediatrics and Head of the Department of Pediatrics B at Soroka University Medical Center, Israel.

As part of the presentation, Professor Tal will review the Company's Phase II clinical trial mid study results  for acute bronchiolitis.

The presentation is scheduled for Sunday, May 18, 2014, as part of the A28 session; " What is new in lung development and early life infection? "

About Nitric Oxide

Nitric oxide is a small, unstable, naturally produced gas that acts as an anti-infection agent, efficient in treating a wide range of diseases. AIT uses nitric oxide in unique dosages and modes of delivery to enable direct, effective access to the lungs.

About AIT

AIT (http://www.ait-pharm.com) is a drug development company focused on the development and commercialization of nitric oxide formulations for the treatment of infectious respiratory diseases such as bronchiolitis, cystic fibrosis, pneumonia, and asthma. The Company was founded by Mor Research Applications, a subsidiary of Clalit Health Services, Israel's largest health management organization. AIT is currently recruiting cystic fibrosis patients for Phase II trials.

Contact information
Racheli Vizman, COO, AIT
2 Derech Meir Weisgal
Rehovot 9632605, Israel
E-mail: racheli@ait-pharm.com
Direct: +972-8-684-3313


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

9000 Executive Park Drive
Building D Suite 300
Knoxville, TN 37923

Phone #: 865-693-4343
Fax #'s:
General: 865-691-6904
Sales: 865-691-6770
Traffic: 865-691-7527

FCC Public File
publicfile@wtnzfox43.com
865-693-4343
EEO Report
Closed Captioning

Powered by WorldNow
All content © Copyright 2000 - 2012 WorldNow and WTNZ. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.